The 4-aminoquinolines, chloroquine and hydroxychloroquine, can suppress chronic graft-versus-host disease (GVHD) following blood and marrow transplantation (BMT) in mice and humans, respectively. We hypothesized that chloroquine in combination with tacrolimus and the rapamycin derivative SDZ-RAD can synergistically suppress T cell responses and antigen-presenting cell (APC) function in vitro. We used the APC-dependent C57BL/6 anti-BALB.B T cell response and APCindependent anti-CD3⑀ antibody-induced response to evaluate the role of synergism between chloroquine and tacrolimus or SDZ-RAD on each component of a T cell response to minor histocompatibility antigens. We found that chloroquine with tacrolimus had a greater synergistic suppression of APC-dependent compared to the APC-independent T cell responses, with a combination index (CIx) for 50% inhibition by mean effect analysis of 0.16 and 0.50, respectively (a lower number indicates greater suppression). By contrast, chloroquine with SDZ-RAD had a similar CIx between the two responsed 0.50 vs 0.45) suggesting only T cell suppression. Synergy between chloroquine and SDZ-RAD involved a direct effect on T cell cytokine production, whereas synergism between chloroquine and tacrolimus was due to an effect on both T cells and APCs. We conclude that the renal-sparing 4-aminoquinolines may be used syneristically with immunosuppressive drugs currently used for BMT. Bone Marrow Transplantation (2002) 30, 905-913.
Graft-versus-host disease (GVHD) is a major obstacle to successful blood and marrow transplantation (BMT) and requires extensive immune suppression therapy. Cyclosporin A is a standard immunosuppressive agent that acts primarily on the T cell component of the GVHD response. Recently, two additional immunosuppressive drugs, tacrolimus and rapamycin, have been shown to have activity against GVHD. Tacrolimus and rapamycin share common anti-fungal and immunosuppressive properties, but exert their immunosuppressive activities through different mechanisms. Tacrolimus inhibits TCR-activated signal transduction pathways and activation of cytokine production. [1] [2] [3] [4] Similar to cyclosporin, tacrolimus has the major drawback of significant renal, hepatic and neurological toxicities. Rapamycin, a macrocyclic lactone similar in structure to tacrolimus, inhibits T cell function and IL-2 responsiveness. 5 In contrast to tacrolimus, rapamycin mediates immune suppression by blocking cytokine, mitogenic and accessory signal responsiveness. Rapamycin has been shown to significantly prolong graft survival in recipients of many types of solid organ allografts and is currently being studied in clinical trials. 6 In BMT studies, rapamycin has been shown to be a highly effective means of reducing the lethality of murine GVHD 7 and in preventing graft rejection. 5 Novartis has recently developed a novel rapamycin derivative, SDZ-RAD, (40-O-(2-hydroxyethyl)-rapamycin, C53H83NO14, molecular weight 958), that has efficiently prevented graft rejection in rat models of allotransplantation. [8] [9] [10] [11] The 4-aminoquinolines, chloroquine and hydroxychloroquine, are lysosomotropic amines that inhibit processing and presentation of MHC class II antigens to CD4 ϩ T cells in vitro. [12] [13] Chloroquine can inhibit the calcium-dependent calmodulin-mediated pathways of T cell activation 14 and IL-2 production by T cells. 15, 16 Hydroxychloroquine has been shown to inhibit TCR-induced intracellular calcium mobilization in a dose-dependent fashion. 17 Our group has shown that chloroquine can decrease GVHD in mice (LP/J donor into C57BL/6; H-2 b , Mls b identical, MLR nonreactive without priming) by decreasing CD4 ϩ and CD8 ϩ T cell responses to minor histocompatibility antigens (MiHC). 13 A recent phase II trial utilizing hydroxychloroquine in steroid refractory chronic GVHD has shown a 50% response rate in humans. 18 Currently, a phase III North American multi-institutional randomized trial evaluating hydroxychloroquine as therapy for chronic GVHD is being performed. The mechanisms of action of hydroxychloroquine are distinct from those of tacrolimus, rapamycin, and cyclosporin and unlike most current immunosuppressive agents, hydroxychloroquine has little renal or hepatic toxicity. If chloroquine has either additive or synergistic immunosuppressive properties with any of the potentially nephrotoxic agents, increased or identical therapeutic efficacy may be achievable with decreased toxicity.
Previously, we have shown that chloroquine and cyclosporine have significant synergism for inhibition of T cell responses in vitro. 12 We hypothesized that chloroquine in combination with either tacrolimus or the rapamycin derivative, SDZ-RAD, would synergistically suppress the T cell responses to MiHC. Since one of the major actions of chloroquine is inhibition of MHC class II antigen presentation, we evaluated the effect of chloroquine in combination with tacrolimus or SDZ-RAD on T cell responses in both an APC-dependent MiHC disparate in vitro model (C57BL/6 anti-BALB.B) and an APC-independent system utilizing anti-CD3⑀ antibody-mediated T cell activation. Mechanistic studies evaluated whether any observed synergism between chloroquine and either tacrolimus or SDZ-RAD on T cells was due to an effect on cytokine production, induction of apoptosis, or decreased response to IL-2.
Methods and materials

Reagents
Cells were cultured in Matis medium, a 1:1 ratio of RPMI:-enriched Eagle's medium supplemented with 10% FBS, 1 ϫ 10 Ϫ5 M 2-ME, 200 mM L-glutamine, 1/100 of 10 4 units penicillin, 10 mg/ml streptomycin, and 20 mM Hepes buffer. RPMI media was obtained from GIBCO (Grand Island, NY, USA). Fetal bovine serum (FBS) was obtained from Hyclone (PDI Joldon, Aurora, Canada). Chloroquine was purchased from Sigma Chemical (St Louis, MO, USA). Chloroquine was suspended in sterile PBS, shielded from light at a concentration of 1 mg/ml and stored at 4°C for not longer than 1 month. Purified tacrolimus (FK 506), a gift of Fujisawa (Deerfield, IL, USA), was dissolved in ethanol at 50 mg/ml and stored at 4°C. SDZ-RAD, a gift from Novartis (Basel, Switzerland), was dissolved in ethanol at 10 mM and stored at 4°C. Human rIL-2 was a gift of Hans-G Klingemann (Terry Fox Laboratories, Vancouver, BC, Canada).
Mice
Three-to four-week-old female C57BL/6 (H-2 b ) mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and BALB.B (H-2 b ) mice from Harlan Labs (Leicestershire, UK). The mice were maintained in the animal care facility at the BC Research Institute for Children's and Women's Health.
Isolation of murine spleen cell subpopulations
Spleen cells were isolated from spleen preparations eluted in Matis medium and passed through a sieve. Cell solutions were centrifuged (4 min at 1500 r.p.m.), and resuspended in 1 ml of RBC lysing solution (0.16 M NH 4 Cl and 0.17 M Tris) for 2 min at room temperature. Nine ml of RPMI medium was added and fat was removed via adherence to a pipette. Cell suspensions were centrifuged and cells were resuspended in 5 ml Matis medium.
T cell priming for minor histocompatibility antigens and proliferation assays
For APC-dependent stimulation, C57BL/6 mice at 5-8 weeks of age were primed by intraperitoneal inoculation with 2.0-2.5 ϫ 10 7 BALB.B spleen cells (H-2 b , MiHC incompatible), as previously described. 13 Spleens were col- For APC-independent T cell stimulation, 0.5 g/well anti-CD3⑀ antibody (clone 145-2C11) was coated on the bottom of a 96-well round-bottomed plate (Falcon, Becton Dickinson Labware, Lincoln Park, NJ, USA) for 18 h at 4°C. Following the addition of T cells, the anti-CD3⑀ proliferative assays were incubated for 2 days, pulsed on day 2 and harvested 18 h later.
T cell purification
T cells were purified with StemSep cell separation system (StemCell Technologies, Vancouver, Canada). Splenocytes were resuspended at 1-4 ϫ 10 8 nucleated cells per ml in PBS/1.5% FBS plus 5% normal rat serum for immunomagnetic labeling. A biotinylated antibody cocktail was added to the cell suspension and incubated for 30 min on ice. An anti-biotin tetrameric antibody was then added and the cells were incubated for 15 min on ice. Magnetic colloid was added to the cell suspension for 30 min on ice. Labeled cells were passed through a metal column contained within a magnetic field. T cells were collected in the column flow through for use in the anti-CD3⑀ stimulated assays. Wells each contained 1 ϫ 10 5 T cells, and combinations of chloroquine, tacrolimus, or SDZ-RAD.
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Apoptosis and viability assays
Splenocytes (1 ϫ 10 6 cells/well) were cultured with anti-CD3⑀ monoclonal antibody in precoated plates, and subjected to different drug treatments. The cultures were kept in a 37°C humidified incubator with 5% CO 2 and assayed following 6 or 24 h incubations. Cell viability was assayed by trypan blue exclusion. For detection of dead or apoptotic cells, cells were washed twice in cold PBS and then resuspended in 1ϫ Annexin V binding buffer (10 mM Hepes/NaOH, 140 mM NaCl, 2.5 mM CaCl 2 , pH 7.4) at a concentration of 1 ϫ 10 6 cells per ml. One hundred l aliquots were then stained by the addition of 5 l of annexin V-FITC and 10 l of propidium iodide, vortexed, and analyzed immediately on a FACSCalibur flow cytometer (BD Immunocytometry Systems, San Jose, CA, USA).
Cytokine assays (IL-2, IFN-γ, IL-4, IL-5)
Murine splenocytes (15 ϫ 10 6 cells/well) were stimulated with anti-CD3⑀ fixed to plastic and cytokine levels evaluated in the media after 24 h. A sandwich ELISA using purified anti-IFN-γ monoclonal antibodies XMG 1.2 and purified, biotinylated R4-6A2 (American Tissue Culture Collection, Rockville, MD, USA) in combination with streptavidin-alkaline phosphatase was carried out as previously described. 19, 20 Internal standards of IFN-γ containing Con A-stimulated mouse spleen cell supernatants calibrated against WHO-NIAID international reference reagent Gg02-901-533 (provided by Dr C Laughlin, NIAID, NIH, Bethesda, MD, USA), were included in each ELISA. Each culture supernatant was evaluated using four two-fold dilutions, carried out in duplicate, falling on the linear portion of the standard curve. IL-4 levels were determined from tissue culture supernatant via an IL-4-specific ELISA utilizing mAb 11B11 for capture and BVD6-24G2 as biotinylated development mAb (BD Pharmingen). IL-2 and IL-5 were also measured by ELISA using cytokine-specific mAb pairs (BD Pharmingen). Detection limits were 0.15 U/ml for IFN-γ, 4 pg/ml for IL-2, 1.2 U/ml for IL-4, 10 pg/ml for IL-5. All samples were measured in at least two assays, with the concentration of each sample calculated from a minimum of two points that fell on the linear portion of the standard curve established using recombinant cytokine standards serially diluted on every assay plate. Inter-assay variability was between 5 and 10% in most circumstances.
Analysis of data
Proliferation data were obtained as raw c.p.m., and converted to ∆c.p.m. by the formula: ∆c.p.m. = mean c.p.m. of triplicate experimental wells minus c.p.m. of triplicate control wells containing cells cultured in the presence of only media. Data were converted to percent inhibition by considering 100% inhibition to be ∆c.p.m. = 0 and 0% inhibition to be ∆c.p.m. of responder cells cultured only with the proliferative stimulus. The percent inhibition by the agents being evaluated was calculated as a percent of the maximum proliferation with none of the immunosuppresBone Marrow Transplantation sive agents present in culture. Each result presented in this study represents the mean of all experiments for each drug concentration with the standard error of the mean (s.e.m.).
Isobologram analysis was calculated by the drug concentrations required to inhibit T cell proliferation by 60%, 70% and 80%. 21, 22 In the isobolograms, expected values were interpolated by a straight line between the concentration of each agent alone that induces the target percent inhibition. Values for combinations of the two agents that cause additive suppression will fall on or near the plotted line of the expected outcome. Values that fall below the line are interpreted as synergistic and those above the line as antagonistic.
The mean effect analysis was performed based on the mean-effect principle of Chou 23 and as we have previously published. 12 The equation states that (fa/fu) = (D/Dm) m where fa is the percentage of inhibition of 3H-thymidine incorporation/100 and the fu is the unaffected (1-fa) by the drug dose D. Dm is the dose required to induce 50% inhibition and m is the coefficient of the sigmoidicity of the dose-effect curve. The equation was converted to a logarithmic equation, which was expressed as: log (fa/fu) = m log DϪm log Dm. A plot of log fa/fu vs log drug concentration was performed whereby m was the slope of the plot and the log Dm as the x-intercept when log (fa/fu) = 0. A linear regression coefficient (r) for goodness of fit was calculated with a minimum r у 0.75 required for the data to obey the median-effect principle underlying the analysis. 
Statistics
Descriptive statistics were generated using StatView for the Macintosh (Abacus Concepts, Berkeley, CA, USA). Data are presented as mean values Ϯ standard error of the mean. Unpaired, one-tailed t-tests were used to compare the means of two groups. The alpha (P) value was set at 0.05, making all P values < 0.05 statistically significant.
Results
Effect of chloroquine in combination with tacrolimus or SDZ-RAD on T cell proliferation to minor histocompatibility antigens
To evaluate the effect of the combination of chloroquine and tacrolimus on T cell priming to MiHC, we used the well-established C57BL/6 anti-BALB.B response. 12, 13 Incubation with tacrolimus or chloroquine alone resulted in significant inhibition of proliferation (Figure 1a and b) . Tacrolimus alone was able to suppress the C57BL/6 anti-BALB. Ϫ5 ng/ml) or of chloroquine (2.5 g/ml) that induced approximately 20% inhibition. This figure represents the average of two experiments presented as the mean difference in proliferation with standard error bars. Maximal proliferation (0% inhibition) was 17175 Ϯ 2070 ∆c.p.m. The increased suppression was statistically significant between chloroquine and chloroquine (2.5 g/ml) plus tacrolimus at 5 ϫ 10 Ϫ5 ng/ml (P Ͻ 0.005) in (a) and between tacrolimus alone (0.0001 ng/ml) and tacrolimus plus chloroquine 2.5 mg/ml in (b). (c and d) Experiments using chloroquine and SDZ-RAD were done exactly as in (a) and (b). Cultures were treated with various concentrations of chloroquine alone, SDZ-RAD alone or either in combination with a fixed concentration of SDZ-RAD (0.05 nM) or of chloroquine (2.5 g/ml) which induced approximately 20% inhibition. This figure represents an average of three experiments with the mean and s.e.m. for each data point. The increased suppression was statistically significant between chloroquine and chloroquine (1 g/ml) plus SDZ-RAD at 0.05 nM (p Ͻ 0.005) in c although not between SDZ-RAD alone (0.01 nM) and SDZ-RAD plus chloroquine 2.5 mg/ml in (d) (P = 0.14).
∆c.p.m.) at a concentration of 7.8 ϫ 10
Ϫ2 ng/ml, 70% at 1.1 ϫ 10 Ϫ1 ng/ml, and 80% at 2.3 ϫ 10 Ϫ1 ng/ml ( Figure  1b) . Chloroquine alone induced 60% suppression at 8 g/ml, 70% suppression at 9.6 g/ml and 80% at 12.9 g/ml (Figure 1a) . We selected concentrations of chloroquine (2.5 g/ml) and tacrolimus (5 ϫ 10 Ϫ5 ng/ml) that induced approximately 20% inhibition (Figure 1a and b) and evaluated suppression of the proliferative response using each agent in combination with a fixed concentration of the other. At a fixed concentration of tacrolimus (5 ϫ 10 Ϫ5 ng/ml) and increasing concentrations of chloroquine there was an even greater suppression of proliferation (Figure 1a) , with 60% suppression at 0.42 g/ml, 70% inhibition at 0.52 g/ml and 80% at 0.64 g/ml of chloroquine. Similar increased suppression was also observed at increasing concentrations of tacrolimus in combination with a fixed concentration (2.5 g/ml) of chloroquine (Figure 1b) .
We evaluated the efficacy of chloroquine and SDZ-RAD in combination in the same MiHC response assay ( Figure  1c and d) . Chloroquine alone induced 60% suppression of the C57BL/6 anti-BALB.B response at a concentration of 4.9 g/ml, 70% suppression at 6.2 g/ml, and 80% at 8.6 g/ml. SDZ-RAD alone induced 60% suppression at 0.5 nM, 70% at 1.2 nM, and 80% at 2.8 nM. Using a fixed concentration of SDZ-RAD (0.05 nM) and increasing concentrations of chloroquine, we observed greater suppression of the C57BL/6 anti-BALB.B response with 60% suppression at 2.8 g/ml, 70% at 4.2 g/ml, and 80% at 6.8 g/ml (Figure 1d) . A similar pattern was seen with a chloroquine concentration of 2.5 g/ml and increasing con-centrations of SDZ-RAD (Figure 1c) . Isobologram evaluation revealed that suppression by chloroquine in combination with both tacrolimus and SDZ-RAD was synergistic at 60%, 70% and 80% suppression of the C57BL/6 anti-BALB.B response (data not shown). These results clearly indicate synergism between chloroquine and either tacrolimus or SDZ-RAD at low concentrations for suppression of T cell responses against minor histocompatibility antigens.
Effect of chloroquine in combination with tacrolimus and SDZ-RAD on APC-independent T cell responses
Because chloroquine can affect both T cell function and antigen presentation, we evaluated the effect of chloroquine combinations directly on T cell activation in the absence of requirement for antigen presentation by using spleen cells activated by immobilized anti-CD3⑀ mAb. The combination of chloroquine (fixed dose of 5 g/ml) and tacrolimus resulted in inhibition of a T cell proliferative response (Figure 2a) . A greater suppression of anti-CD3⑀-induced T cell proliferation was observed using increasing concentrations of chloroquine with tacrolimus (5 ϫ 10 Ϫ3 ng/ml) ( Figure 2b) .
Inhibition of anti-CD3⑀-induced T cell proliferation by chloroquine alone required 5 g/ml for 20% inhibition and by SDZ-RAD alone required 0.01 nM for 7% inhibition. In combination, however, 65% suppression was achieved with chloroquine (5 g/ml) and SDZ-RAD (0.05 nM) ( Figure  2c ). Increased suppression (37%) was also seen with SDZ-RAD (0.01 nM) and chloroquine (5 g/ml) (Figure 2d ). Isobologram evaluation revealed synergism for the combination of chloroquine with either tacrolimus or SDZ-RAD at 60%, 70% and 80% suppression.
Mean effect analysis comparison for synergism in APCdependent APC-independent responses by T cells
An alternate method to evaluate for synergism is to use mean effect analyses in which a combination index (CIx) for 50% inhibition is calculated, allowing for direct comparison of the synergistic effect of different drug combinations. The advantage of this method is that it allows for a quantitative comparison of synergism for different drug combinations. We used the following interpretive scale as previously reported: 24 CIx Ͼ 1.0 is antagonistic; CIx = 1 is additive; CIx = 0.9-0.6 is synergistic; CIx = 0.5-0.1 is strongly synergistic; and CIx Ͻ 0.1 is very strongly synergistic. The APC-dependent (C57BL/6 anti-BALB.B) response is dependent on both T cells and APCs whereas as the APC-independent response (anti-CD3⑀ stimulation of purified T cells) evaluates only T cells. Comparison of the CIx between the two assays allows for quantitative comparison of the relative impact of a drug on T cells compared to T cells and APCs. As an example, if the CIx for the APC-dependent response is lower (indicating more synergism) than the APC-independent response, the additional synergisms can be attributed to drug effects on other accessory cell populations. However, if the CIx is similar for both the APC-dependent and APC-independent response, all synergism can be attributed to the effect of the drug combination on T cells.
In this study, the CIx for chloroquine and tacrolimus demonstrated strong synergy with a value of 0.16 on the antigen-dependent response compared to a lower synergism (CIx = 0.50) for the APC-independent response (Table 1) . Thus, synergistic suppression of the T cell response to MiHC was secondary to effects on both T cells and antigen presentation. The CIx from the combination of chloroquine and SDZ-RAD for the C57BL6 anti-BALB.B response was 0.59, similar to the anti-CD3⑀-induced response (0.45). The similar CIx for chloroquine with SDZ-RAD supports the conclusion that synergistic suppression of the APC-dependent response is primarily due to suppression of T cells.
Effect of chloroquine in combination with tacrolimus and SDZ-RAD on T cell death
One possible explanation for the synergistic suppression of both APC-dependent and independent T cell proliferative responses may be increased induction of T cell apoptosis by the drug combinations. We evaluated whether the decreased T cell proliferative response for chloroquine in combination with either SDZ-RAD or tacrolimus was secondary to increased T cell death. T cell viability was assessed by both propidium iodine and annexin V-FITC double staining and trypan blue exclusion. T cells exposed to increasing concentrations of chloroquine, tacrolimus and SDZ-RAD, alone or in combination, revealed that there was no increase in apoptosis with any of the drug combinations or at the highest dosages at either 6 or 24 h (data not shown).
Evaluation for direct effect of chloroquine in combination with tacrolimus and SDZ-RAD on splenocyte cytokine production
Cyclosporin, tacrolimus and chloroquine have all previously been shown to decrease cytokine production as a major mechanism for their immunosuppressive effects. We investigated whether the observed synergism between chloroquine and the other drugs was due to synergistic suppression of cytokine production by splenocytes. To account for potential secondary cytokine production by T cells and other accessory populations, spleen cells were stimulated by anti-CD3⑀. Drug concentrations that individually induced approximately 20% inhibition of splenocyte proliferation were used either alone or in combination. The combination of chloroquine and tacrolimus induced less inhibition of IL-2 (4 Ϯ 5%, mean Ϯ s.e.m.), IFN-γ 13 Ϯ 3%), IL-4 (21 Ϯ 3%) and IL-5 (7 Ϯ 2%) production than seen with chloroquine or tacrolimus alone (Figure 3) . By contrast, the combination of chloroquine and SDZ-RAD resulted in greater inhibition of IL-2, IFN-γ, IL-4, and IL-5 production by splenocytes (Figure 3b) . Calculation of the CIx by mean effect analysis or isobologram analysis was not possible since limited drug concentrations were utilized in these assays.
Effect of exogenous IL-2 on synergistic suppression of T cell proliferative responses
Previously, rapamycin has been shown to not only inhibit IL-2 production but also IL-2 responsiveness. SDZ-RAD is a rapamycin derivative, we evaluated whether part of the synergism between chloroquine and either SDZ-RAD or tacrolimus may be due to synergistic suppression of IL-2 responsiveness. Exogenous human rIL-2 (10 units/ml) was added in culture medium with chloroquine (5 g/ml), tacrolimus (5 ϫ 10 Ϫ3 ng/ml), SDZ-RAD (0.05 nM), alone or in combination. Similar T cell suppression was found when incubating T cells with each drug alone without the presence of IL-2 (chloroquine, 40%; tacrolimus 60%; SDZ-RAD 48%). More suppression of T cell proliferation was seen by chloroquine in combination with SDZ-RAD or tacrolimus when no exogenous IL-2 was present in the culture medium (chloroquine ϩ tacrolimus, 87%; chloroquine ϩ SDZ-RAD, 75%). Exogenous IL-2 could rescue the suppression of T cells by tacrolimus (30%), but there was no correction of the T cell proliferative response inhibited by chloroquine (42%) or SDZ-RAD (46%) at either 10 U/ml or 50 U/ml. Exogenous IL-2 (10 U/mL) appeared to only partially correct the direct inhibition of T cells by chloroquine in combination with tacrolimus (chloroquine ϩ tacrolimus, 87% to 58%), with no correction of the inhibition by chloroquine and SDZ-RAD (75% vs 70%). Higher concentrations of IL-2 (50 U/ml) did not alter this pattern, suggesting that induction of IL-2 nonresponsiveness in either combination was not the mechanism of synergism (Figure 4 ).
Discussion
Understanding how synergism occurs is important for the rational design of immune suppressive approaches to control GVHD and graft rejection. The 4-aminoquinolines, hydroxychloroquine and chloroquine, are becoming gener- Table 1 Synergism between chloroquine, and tacrolimus, cyclosporine or SDZ-RAD on antigen-dependent and -independent T cell responses using mean effect analysis Fixed dose tacrolimus C57BL6 anti-BALB.B was 5 ϫ 10 Ϫ5 ng/ml and anti-CD3⑀ was 5 ϫ 10 Ϫ3 ng/ml, for SDZ-RAD C57BL6 anti-BALB.B and anti-CD3⑀ was 0.05 nM, and for chloroquine for C57BL/6 anti-BALB.B was 2.5 g/ml and for anti-CD3⑀ was 5 g/ml. All of the correlation coefficients (r) were greater than 0.75, except 0.61 of chloroquine in combination with tacrolimus. CIx = the combination index for 50% inhibition. We used the following interpretive scale as previously reported: 24 CIx Ͼ 1.0 is antagonistic; CIx = 1 is additive; CIx = 0.9-0.6 is synergistic; CIx = 0.5-0.1 is strongly synergistic; and CIx Ͻ 0.1 is very strongly synergistic. The CIx was reproducible to within Ϯ 0.1 from experiment to experiment with an identical proportional relationship.
ally accepted immune suppressive agents to control GVHD after BMT. 18, 27 One of the unique aspects of this group of drugs is their ability to inhibit not only T cell function, but also MHC class II antigen presentation. Thus, synergy between chloroquine and other T cell-specific agents may be due to a combined effect on both the T cell and APC compartments. In this study, we determined that the synergistic suppression observed with tacrolimus and chloroquine involved inhibition of both antigen presentation and T cell function, since suppression was three times greater (CIx lower) in the APC-dependent C57BL/6 anti-BALB response than in the APC-independent response. By contrast, synergistic suppression by chloroquine and SDZ-RAD appeared to be due solely to a direct effect on T cells as the CIx of both responses were equivalent.
Chloroquine has been shown to inhibit IL-2 production by T cells. 15, 16 In the drug combination experiments reported here, we show some suppression of production of Th1 cytokines, IL-2 and IFN-γ and Th2 cytokines, IL-4 and IL-5, at drug concentrations that can inhibit proliferation by 20%. Although tacrolimus is a potent inhibitor of IL-2 production, 2,3 it caused little inhibition of either Th1 or Th2 cytokine production at the low drug concentrations used in the synergism evaluations. Our results show that the synergistic suppression of T cell responses with chloroquine and tacrolimus was not mediated by suppression of the Th1 and Th2 cytokine production. In the case of the chloroquine and SDZ-RAD, however, the combination of drugs resulted in increased inhibition of cytokine production, suggesting a role for this mechanism in drug synergy. In our experi- (15 x 10 6 ) were stimulated with anti-CD3⑀ fixed to plastic, and cytokine levels were evaluated in the media after 24 h. Fixed doses of chloroquine (2.5 g/ml), tacrolimus (5 ϫ 10 Ϫ5 ng/ml) and SDZ-RAD (0.05 nM) were used in evaluation of drug combination. This figure represents the average of three experiments, and each symbol represents the mean inhibition with s.e.m. There were no statistically significant differences in (a). There was a significant difference between chloroquine alone and chloroquine plus SDZ-RAD for IFN-γ, IL-4, IL-5 (P р 0.01) and IL-2 (P р 0.05) and between SDZ-RAD alone and SDZ-RAD plus chloroquine for IL-4 and IFN-γ (P р 0.01). (b). ments, we observed correction of the suppressive effects of tacrolimus, but not chloroquine or SDZ-RAD, with lowdose IL-2, indicating that the synergism between chloroquine and tacrolimus is not due to increased inhibition of IL-2 signaling. 28, 29 Taken together, these results suggest that suppression of T cell cytokine production induced by SDZ-RAD with chloroquine represents one of the primary mechanisms for the direct inhibition of T cells by this combination, but the synergistic suppression of T cell responses induced by chloroquine with tacrolimus was due to other effects on T cells. The inhibition of early activation events was not investigated in this study and may be involved in the suppression by chloroquine with tacrolimus. Importantly, the induction of additional apoptosis was not responsible for the increased suppression of either drug combination.
In summary, this is the first observation that a 4-aminoquinoline, chloroquine, can synergistically suppress both APC-dependent and APC-independent T cell responses in combination with the rapamycin derivative, SDZ-RAD, or tacrolimus. The synergisms of chloroquine and SDZ-RAD or tacrolimus appear to be mediated through different pathways, with tacrolimus and chloroquine affecting both APC and T cell function whereas the chloroquine and SDZ-RAD combination has a primary effect on T cell proliferation and cytokine production. Chloroquine and hydroxychloroquine would represent important additions for combination therapy since they do not produce the significant renal toxicity observed with the other drugs. The combination of immune suppressive drugs whose primary effect is on T cells with drugs that have unique effects on MHC class II antigen presentation, such as chloroquine or hydroxychloroquine, may also lead to increased therapeutic efficacy.
